• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Ghanaian and Novartis researchers build scientific bridges
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Access to Healthcare

Ghanaian and Novartis researchers build scientific bridges

Emerging markets in Africa are gearing up for clinical research. Learn how Novartis is working with Ghana and Kenya to build research capacity.

Feb 08, 2013

During the summer in 2012, six science research fellows from Ghana visited NIBR Cambridge working closely with NIBR researchers across various disease areas and scientific platforms.



Through fellowships and internships, students of research, medicine, nursing or pharmacy from developing nations can gain practical knowledge in the discovery and development of new therapeutic drugs, and the delivery of medical care.

“I knew my students could benefit greatly from the visit to NIBR in Cambridge, and they all had wonderful things to say about their laboratory experiences," says Karen Duca, Associate Professor, Clinical and Medical Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology (KNUST) in Kumasi, Ghana.

Their experience catalyzed the idea for NIBR scientists to visit Ghana later in the year to conduct educational workshops for the wider KNUST university research community

"Through these workshops, many of the junior scientists who couldn't go to Cambridge were exposed to world-class drug discovery training, and they saw what their potential could be and a path to achieve it," says Karen.

Building connections between Novartis and African scientists and medical communities is critical to solving major health problems that impact millions of people in Africa.

Tags: 
Novartis Institutes for BioMedical Research, Drug Development
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Dr. Theophile Tuyisabe standing next to his patients smiling at him
Access to Healthcare

Meet a visionary who beat the odds to realize his vision of inclusive eye care

Access to Healthcare

Chagas disease: Breaking the silence

Sandoz in Kalwe, India ensures multidrug therapy (MTD) supply to WHO to fight leprosy
Access to Healthcare

Ensuring medicine supply to patients during COVID-19

You are here

  1. Home ›
  2. Stories ›
  3. Access healthcare

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.